Miglustat / OGT 918 in the Treatment of Cystic Fibrosis

This study has been terminated.
(Methodology applied did not meet all criteria required per guidelines)
Information provided by:
ClinicalTrials.gov Identifier:
First received: September 28, 2007
Last updated: February 11, 2010
Last verified: February 2010
Cystic fibrosis is a genetic disease caused by mutation of the cystic fibrosis transmembrane conductance regulator (CFTR). The purpose of the study is to investigate the effects of miglustat on CFTR function in cystic fibrosis patients.

Condition Intervention Phase
Cystic Fibrosis
Drug: miglustat
Drug: placebo
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Single Center, Double-blind, Randomized, Placebo-controlled, 2-period/2-treatment Crossover Study Investigating the Effect of Miglustat on the Nasal Potential Difference in Patients With Cystic Fibrosis Homozygous for the ΔF508 Mutation

Resource links provided by NLM:

Further study details as provided by Actelion:

Primary Outcome Measures:
  • Change in nasal potential difference (NPD) in response to isoproterenol in chloride-free buffer in the presence of amiloride [ Time Frame: Baseline (pre-dose on day 1) to end-of-treatment (day 8) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Change in baseline NPD response [ Time Frame: Baseline to end-of-treatment ] [ Designated as safety issue: No ]

Enrollment: 6
Study Start Date: November 2007
Study Completion Date: March 2008
Primary Completion Date: February 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: A
Oral miglustat capsules 200 mg t.i.d. for 1 week and a single 200 mg dose on day 8
Drug: miglustat
Other Names:
  • Zavesca
  • OGT 918
  • 1.5- (Butylimino) -1.5- Dideoxy-D-Glucitol
Placebo Comparator: B
Oral placebo capsules matching in appearance miglustat capsules given t.i.d. for 1 week and a single dose on day 8
Drug: placebo


Ages Eligible for Study:   12 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Aged 12 years and older
  • Male or female
  • Non-pregnant women who are to remain non-pregnant for 3 months after the end of the study: only women who are surgically sterile, who are in the menopause (no menstruation for at least one year) or those of childbearing potential who are using a reliable method of contraception. Reliable methods of contraception for female patients include the following:

    • Barrier type devices (e.g., female condom, diaphragm and contraceptive sponge) used ONLY in combination with a spermicide
    • Intrauterine devices
    • Oral contraceptive agent
    • Depo-Provera™ (medroxyprogesterone acetate)
    • Levonorgestrel implants Abstention, the rhythm method or contraception by the partner alone are NOT reliable methods of contraception.

For children, a reliable method of contraception must be considered, if appropriate.

  • Accepting for the duration of the study and for 3 months thereafter to use a condom and not to procreate a child (males only)
  • Cystic fibrosis patients homozygous for the ΔF508 mutation as confirmed by genetic test
  • Signed informed consent prior to any study-mandated procedure

Exclusion Criteria:

  • Any condition prohibiting the correct measurement of the NPD such as upper respiratory tract infection
  • Acute upper respiratory tract or pulmonary exacerbation requiring antibiotic intervention within 2 weeks of screening
  • Severe renal impairment (creatinine clearance < 30 ml/min as per Cockroft and Gault)
  • Female patients who will not undergo a pregnancy test prior to enrollment in the study
  • History of significant lactose intolerance
  • History of neuropathy
  • History of cataracts or known increased risk of cataract formation
  • Presence of clinically significant diarrhea (>3 liquid stolls per days for >7 days) without definable cause within 1 month prior to screening
  • Any known factor of disease that might interfere with treatment compliance, study conduct or interruption of the results such as drug or alcohol dependence or psychiatric disease
  • FEVI <25% of predicted normal
  • Oxygen saturation at rest <88%
  • Active or passive smoking as measured using the Smokelyzer®
  • Hypersensitivity to miglustat or any excipients
  • Planned treatment or treatment with another investigational drug or therapy (e.g., gene therapy) within 1 month prior to randomization
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00537602

Corporacio Parc Tauli / Parc Tauli Hospital
Barcelona, Spain
Sponsors and Collaborators
Study Director: Paul van Giersbergen, PhD Actelion
Principal Investigator: Christian Domingo-Ribas, MD Corporacio Parc Tauli
  More Information

Additional Information:
No publications provided

Responsible Party: Paul van Giersbergen , PhD, Actelion
ClinicalTrials.gov Identifier: NCT00537602     History of Changes
Other Study ID Numbers: AC-056-201
Study First Received: September 28, 2007
Last Updated: February 11, 2010
Health Authority: Spain: Ethics Committee
Spain: Spanish Agency of Medicines

Keywords provided by Actelion:
cystic fibrosis
nasal potential difference
transmembrane conductance regulator (CFTR)

Additional relevant MeSH terms:
Cystic Fibrosis
Digestive System Diseases
Genetic Diseases, Inborn
Infant, Newborn, Diseases
Lung Diseases
Pancreatic Diseases
Pathologic Processes
Respiratory Tract Diseases
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses

ClinicalTrials.gov processed this record on November 25, 2015